Tag: Sotatercept

PAH

Merck’s Pulmonary Arterial Hypertension Drug Sotatercept Phase III Clinical Success

ADC评论 October 13, 2022

Merck announced that the Phase III STELLAR clinical study of sotatercept in pulmonary arterial hypertension (PAH) achieved positive top-line results, meeting the primary endpoint and

Sotatercept

Merck’s $11.5 billion acquisition of Sotatercept successfully phase 3 clinical trial

ADC评论 October 11, 2022

On October 10, Merck announced that its potential “first-in-class” therapy sotatercept met the primary clinical endpoint in a Phase 3 clinical trial for the treatment

Latest Articles

azide peg linker click chemistry

Leveraging Azide PEG in Biopharmaceuticals: Uniting Azide Linkers and Click Chemistry

October 20, 2023

peg-tco

TCO-Functionalized PEG Derivatives: Versatile Tools for Bioconjugation

October 16, 2023

Tetrazine PEG

Tetrazine and Methyltetrazine: Structural Distinctions and Their Roles in Pharmaceutical Research

October 8, 2023

endo bcn, exo bcn, bcn peg

BCN Compounds in Pharmaceutical Research and Development

October 6, 2023

cydyes

An Overview of Cyanine Dyes: Types, Wavelengths, and Applications Across Industries

September 19, 2023

Protein Conjugation

Unveiling the Power of Protein Conjugation: The Biochemical Game Changer

May 26, 2023

Hot Articles